Refractory migraine profile in CGRP‐monoclonal antibodies scenario
Acta Neurologica Scandinavica2021Vol. 144(3), pp. 325–333
Citations Over TimeTop 10% of 2021 papers
Marcello Silvestro, Alessandro Tessitore, Fabrizio Scotto di Clemente, Giorgia Battista, Gioacchino Tedeschi, Antonio Russo
Abstract
We outline that higher frequency of migraine attacks, medication overuse and pain catastrophizing characterize patients with Ref-M not responsive to CGRP-mAbs. In this frame, olanzapine effectiveness on frequency and pain intensity of migraine attacks supports the hypothesis that migraine refractoriness may be subtended by a prominent involvement of the dopaminergic pathway.
Related Papers
- → Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention(2015)316 cited
- → Hypersensitivity to calcitonin gene-related peptide in chronic migraine(2020)38 cited
- → Is calcitonin gene-related peptide a reliable biochemical marker of migraine?(2022)23 cited
- → Field Testing Alternative Criteria for Chronic Migraine(2006)58 cited
- → Plasma Calcitonin Gene-Related Peptide in Diagnosing and Predicting Paediatric Migraine(2009)53 cited